Biotech Gainers: Geron Corporation (NASDAQ:GERN), Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA), Idera Pharmaceuticals Inc. (NASDAQ:IDRA), Opexa Therapeutics Inc. (NASDAQ:OPXA)

Technology Stocks News 3

Brower Piven, A Professional Corporation announces that a class action lawsuit has been commenced in the United States District Court for the Northern District of California on behalf of purchasers of Geron Corporation (NASDAQ:GERN) securities during the period between June 16, 2013 and March 11, 2014, inclusive (the “Class Period”). Geron Corporation (NASDAQ:GERN) stock performance was 39.33% in last session and finished the day at $2.48. Traded volume was 39.03 million shares in the last session and the average volume of the stock remained 5.55 million shares. The beta of the stock remained 1.57. Geron Corporation (NASDAQ:GERN) insider ownership is 0.10%.

Even after a resurrected sales approval from the Federal Drug Administration Authority in the US Ariad Pharmaceuticals Inc. (NASDAQ:ARIA)’s shares are still facing the brunt of the October recall of Iclugis. Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) rose 5.56% to $8.35 yesterday on volume of 13.61 million shares. The intra-day range of the stock was $7.91 – $8.42. Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) has a market capitalization of 1.55 billion.

Idera Pharmaceuticals (NASDAQ:IDRA) issued its quarterly earnings data on Thursday. The company reported ($0.10) earnings per share for the quarter, missing the analysts’ consensus estimate of ($0.08) by $0.02, Stock Ratings Network reports. Idera Pharmaceuticals Inc. (NASDAQ:IDRA)’s stock on March 18, 2014 reported a higher of 8.75% to the closing price of $6.59. Its fifty two weeks range is $0.43 – $6.87. The total market capitalization recorded 301.29 million. The overall volume in the last trading session was 7.65 million shares. In its share capital, Idera Pharmaceuticals Inc. (NASDAQ:IDRA) has 45.72 million outstanding shares.

Opexa Therapeutics, Inc. (NASDAQ:OPXA) is a biopharmaceutical company. The Company is engaged in developing personalized cellular therapies with the potential to treat illnesses, including multiple sclerosis (MS). On Tuesday, shares of Opexa Therapeutics Inc. (NASDAQ:OPXA) advanced 14.81% to close the day at $2.17. Company return on investment (ROI) is – and its monthly performance is recorded as 26.16%. Opexa Therapeutics Inc. (NASDAQ:OPXA) quarterly revenue growth is 13.02%.

Signup for free to be the first to receive exclusive free links. Now in your mailbox!
Join over 15,000 subscribers
Send me links

Your information will not be shared to anyone